In 2001 valproate, a gamma-aminobutyric acid (GABA) agonist with a long history of clinical use for treatment of epilepsy and mood disorders (reviewed in [8]), was identified having HDAC inhibitory activity. This evidence concerns the gene HDAC9 and epilepsy.